Anti-tuberculosis Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Anti-tuberculosis Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Anti-tuberculosis (TB) Therapeutics Market is expected to witness a CAGR of 6.2% during the forecast period (2022 - 2027).

The COVID-19 pandemic had a significant impact on the healthcare systems, with significant consequences not only for COVID-19-infected patients but also for others, resulting in the cancellation of diagnosis and treatment services to manage and reserve resources, and many hospitals are experiencing a shortage of professionals to assist with these diagnostic and treatment procedures. The COVID-19 restrictions imposed by the government have impacted the market growth. For instance, according to the data published by the World Health Organization, in March 2021, titled 'Impact of the COVID-19 pandemic on TB detection and mortality in 2020', it has been observed that an estimated 1.4 million fewer persons underwent TB treatment in 2020 than in 2019, a 21% decrease from 2019. Additionally, as per an article published by the International Journal of Tuberculosis and Lung Disease, in June 2021, titled 'The impact of COVID-19 on TB: a review of the data, it has been observed that the provision of tuberculosis services has been hampered with high TB burden due to inadequate capacity and equipment, restrictions on migration (affecting health care staff, supplies, and stock), and resource reallocation. Also, tuberculosis patients have struggled to get TB services, either due to fear of SARS-CoV-2 infection, fear of stigma, mobility restrictions, shortened health facility operating hours, or reduced financial resources to pay for care or transportation. As a result, TB diagnosis, treatment, and prevention have been impacted globally. Thus, COVID-19 has significantly impacted the market growth during the pandemic.

Certain factors that are propelling the market growth are the rising prevalence of tuberculosis, a growing initiative from government organizations for tuberculosis awareness, and the rising incidence of multi-drug resistant (MDR) and extensively drug-resistant tuberculosis (XDR) cases in developing countries.

The COVID-19 pandemic had a significant impact on the healthcare systems, with significant consequences not only for COVID-19-infected patients but also for others, resulting in the cancellation of diagnosis and treatment services to manage and reserve resources, and many hospitals are experiencing a shortage of professionals to assist with these diagnostic and treatment procedures. The COVID-19 restrictions imposed by the government have impacted the market growth. For instance, according to the data published by the World Health Organization, in March 2021, titled 'Impact of the COVID-19 pandemic on TB detection and mortality in 2020', it has been observed that an estimated 1.4 million fewer persons underwent TB treatment in 2020 than in 2019, a 21% decrease from 2019. Additionally, as per an article published by the International Journal of Tuberculosis and Lung Disease, in June 2021, titled 'The impact of COVID-19 on TB: a review of the d, it has been observed that the provision of tuberculosis services has been hampered with high TB burden due to inadequate capacity and equipment, restrictions on migration (affecting health care staff, supplies, and stock), and resource reallocation. Also, tuberculosis patients have struggled to get TB services, either due to fear of SARS-CoV-2 infection, fear of stigma, mobility restrictions, shortened health facility operating hours, or reduced financial resources to pay for care or transportation. As a result, TB diagnosis, treatment, and prevention have been impacted globally. Thus, COVID-19 has negatively impacted the market growth during the pandemic.

Additionally, the rising incidence of multi-drug resistant tuberculosis (MDR-TB) and XDR in developing countries is also expected to boost market growth over the forecast period. For instance, according to an article published by the Journal of Family Medicine and Primary Care, in January 2022, titled 'Status of drug-resistant tuberculosis among patients attending a tuberculosis unit of West Bengal', it has been observed that the prevalence of tuberculosis and multidrug-resistant tuberculosis (MDR-TB) is highest in India and ranks first in the global ranking of detecting new cases each year. In addition, as per the same source, an estimated overall incidence of tuberculosis in India was 193 per lakh people, in 2020.

Furthermore, the growing government initiatives in creating awareness among the population regarding tuberculosis (TB) are also expected to propel market growth over the forecast period. For instance, in March 2021, Dr. Harsh Vardhan, Union Minister for Health and Family Welfare launched the ‘Tribal TB Initiative’ along with Shri Arjun Munda, Union Minister for Tribal Affairs in the presence of Shri Ashwini Kumar Choubey, Minister of State for Health and Family Welfare in India. Also, in July 2019, the State Council of China released the Healthy China Initiative 2019–2030, which included 15 special campaigns, including the Tuberculosis Control Action to guide the way for China’s TB prevention and control. Hnece, these factors are expected to boost the market growth.

However, the adverse side effects of anti-tuberculosis drugs and the high cost of MDR and XDR TB drugs are likely to impede the market growth over the forecast period.

Key Market TrendsIsoniazid Segment Expects to Register a High CAGR in the Anti-tuberculosis Therapeutics Market Over the Forecast Period

Isoniazid, also known as an isonicotinic acid hydrazide, is an antibiotic used for the treatment of tuberculosis. It inhibits InhA, the enoyl reductase from Mycobacterium tuberculosis, by forming a covalent adduct with the NAD cofactor.

The isoniazid segment is expected to witness significant growth in the anti-tuberculosis therapeutics market over the forecast period owing to the factors such as the rising prevalence of tuberculosis and the adoption of isoniazid as a treatment for tuberculosis and the rising company activities in conducting clinical trials. For instance, according to an article published by the American Journal of Respiratory and Critical Care Medicine, in June 2020, titled ‘High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis’, it has been observed that the high dose isoniazid has an early bactericidal activity for Mycobacterium tuberculosis (MTB) strains with inhA mutations. In addition, as per the same source, for individuals with isolated inhA mutations and rifampicin-resistant tuberculosis (TB), high-dose isoniazid is a helpful addition to second-line TB therapy regimens. This is expected to increase the growth of the segment, thereby propelling the market growth over the forecast period.

Also, in February 2021, five African countries, namely Ethiopia, Ghana, Kenya, Mozambique, and Zimbabwe, have piloted a new short-short course tuberculosis treatment regime, a fixed dose-combination of rifapentine and isoniazid, that helps in reducing the pills burden from nine to three pills a week for adults. Thus, the increasing adoption of isoniazid in combination with other drugs for treating tuberculosis is expected to fuel the segment growth over the forecast period.

Therefore, the due to aforementioned factors the studied market is expected to increase over the forecast period.

North America Dominates the Market and Expects to do Same Over the Forecast Period

North America is expected to dominate the tuberculosis therapeutics market owing to the factors such as the rising number of tuberculosis cases in the region, the presence of well-established healthcare infrastructure, and high healthcare spending.

The rising incidence of tuberculosis in the region is the key factor driving the market growth. For instance, according to the Centers for Disease Control and Prevention’s National Tuberculosis Surveillance System (NTSS), a total of 7,860 tuberculosis cases were reported in the 50 United States and the District of Columbia (DC), in 2021. The national incidence of reported tuberculosis cases (cases per 100,000 people) increased by 9.4% in 2021 (2.37) as compared to 2020. In addition, as per the same source, the increase in tuberculosis cases among the population in 2021 was due to the delayed diagnosis of cases in persons with symptom onset during 2020. Also, as per the same source, in 2021, some of the countries with the highest number of tuberculosis cases were California (1,750), Texas (991), Florida (499), Pennsylvania (166), Ohio (149), and Arizona (129). Thus, the growing burden of tuberculosis among the population is expected to raise the demand for effective drugs which is expected to increase the market growth over the forecast period.

In addition, the rising healthcare spending in the region is expected to increase the company’s activities for developing effective and safe drugs, thereby propelling the market growth. For instance, according to the Organization for Economic Co-operation and Development (OECD), 2022, United States healthcare spending, as percent share of GDP, in 2021 was around 17.8%. Additionally, as per the data published by the Centers for Medicare & Medicaid Services (CMS), in March 2022, titled “CMS Office of the Actuary Releases 2021-2030 Projections of National Health Expenditures”, it has been observed that the annual growth in national health spending is expected to average 5.1% over 2021-2030. In addition, the National Health Spending in 2020 was USD 4.1 trillion and it is projected to reach USD 6.8 trillion by 2030.

Therefore, the due to aforementioned factors the studied market is expected to increase over the forecast period.

Competitive Landscape

The anti-tuberculosis therapeutics market is highly consolidated, with very few companies holding a substantial market share. With the rising focus of the healthcare sector on the development of novel drugs and the growing investment in research and development, more small to mid-sized companies are estimated to enter the market in the coming future. Some of the companies in the market are Lupin, Macleods Pharmaceuticals Ltd, Otsuka Pharmaceutical Co. Ltd, and Johnson and Johnson holds the largest market share.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.